Syntara Drug Slows Motor Decline in Early Parkinson’s Risk Group, Placebo Worsens [VIDEO]

Syntara SNT-4728 Parkinson's Phase 2 results show a statistically significant motor improvement (p=0.021) that held 12 weeks after dosing, backing up earlier evidence of reduced brain inflammation.

By Josua Ferreira -

Key Takeaways

  • SNT-4728 beat placebo on clinician-assessed motor signs at Week 24 (p=0.021, MDS-UPDRS Part III), 12 weeks after treatment ended.
  • The result is the second positive readout in the study, following the 6 July 2026 TSPO PET finding (p=0.0145) with 67% of participants showing reduced putamen inflammation.
  • The SNT-4728 group improved while placebo deteriorated, and no treatment-related serious adverse events were reported in the 41-participant, 3:1 randomised study.
  • The smartphone motor composite was directionally consistent but not statistically significant, and other measures including MoCA, SF-36 and RBDQ showed no marked change.
  • No new trial, timeline or funding was announced, so the next catalyst is a further study design after Professor Lewis presents in Seoul on 7 October 2026.
This is a special feature video produced for our partner.

Breaking ASX Alerts Direct to Your Inbox

Join +20,000 subscribers receiving alerts.

Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.

About the Publisher